Taiwan
· Delayed Price · Currency is TWD G&E Herbal Biotechnology Statistics
Total Valuation
G&E Herbal Biotechnology has a market cap or net worth of TWD 2.99 billion. The enterprise value is 2.67 billion.
| Market Cap | 2.99B |
| Enterprise Value | 2.67B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | Aug 20, 2024 |
Share Statistics
G&E Herbal Biotechnology has 55.66 million shares outstanding. The number of shares has increased by 0.10% in one year.
| Shares Outstanding | 55.66M |
| Shares Change (YoY) | +0.10% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 37.80.
| PE Ratio | 37.80 |
| Forward PE | n/a |
| PS Ratio | 15.00 |
| PB Ratio | 4.09 |
| P/FCF Ratio | 23.12 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.83, with an EV/FCF ratio of 20.63.
| EV / Earnings | 31.82 |
| EV / Sales | 12.63 |
| EV / EBITDA | 25.83 |
| EV / EBIT | 28.56 |
| EV / FCF | 20.63 |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.28.
| Current Ratio | 3.61 |
| Quick Ratio | 3.39 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.02 |
| Interest Coverage | 4,059.43 |
Financial Efficiency
Return on equity (ROE) is 11.20% and return on invested capital (ROIC) is 7.78%.
| Return on Equity (ROE) | 11.20% |
| Return on Assets (ROA) | 7.09% |
| Return on Capital (ROIC) | 7.78% |
| Revenue Per Employee | 5.71M |
| Profits Per Employee | 2.27M |
| Employee Count | 37 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.59% |
| 50-Day Moving Average | 54.49 |
| 200-Day Moving Average | 55.13 |
| Relative Strength Index (RSI) | 45.23 |
| Average Volume (20 Days) | 12,791 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, G&E Herbal Biotechnology had revenue of TWD 211.15 million and earned 83.82 million in profits. Earnings per share was 1.42.
| Revenue | 211.15M |
| Gross Profit | 170.74M |
| Operating Income | 93.37M |
| Pretax Income | 104.80M |
| Net Income | 83.82M |
| EBITDA | 102.56M |
| EBIT | 93.37M |
| Earnings Per Share (EPS) | 1.42 |
Balance Sheet
The company has 324.13 million in cash and 2.21 million in debt, giving a net cash position of 321.92 million or 5.78 per share.
| Cash & Cash Equivalents | 324.13M |
| Total Debt | 2.21M |
| Net Cash | 321.92M |
| Net Cash Per Share | 5.78 |
| Equity (Book Value) | 774.65M |
| Book Value Per Share | 13.13 |
| Working Capital | 258.41M |
Cash Flow
In the last 12 months, operating cash flow was 133.14 million and capital expenditures -3.84 million, giving a free cash flow of 129.30 million.
| Operating Cash Flow | 133.14M |
| Capital Expenditures | -3.84M |
| Free Cash Flow | 129.30M |
| FCF Per Share | 2.32 |
Margins
Gross margin is 80.86%, with operating and profit margins of 44.22% and 39.70%.
| Gross Margin | 80.86% |
| Operating Margin | 44.22% |
| Pretax Margin | 49.64% |
| Profit Margin | 39.70% |
| EBITDA Margin | 48.57% |
| EBIT Margin | 44.22% |
| FCF Margin | 61.24% |
Dividends & Yields
This stock pays an annual dividend of 0.54, which amounts to a dividend yield of 1.00%.
| Dividend Per Share | 0.54 |
| Dividend Yield | 1.00% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.10% |
| Shareholder Yield | 0.90% |
| Earnings Yield | 2.65% |
| FCF Yield | 4.33% |
Stock Splits
The last stock split was on August 20, 2024. It was a forward split with a ratio of 1.06.
| Last Split Date | Aug 20, 2024 |
| Split Type | Forward |
| Split Ratio | 1.06 |